Clene

Clene Pre-Tax Margin

The Pre-Tax Profit Margin of Clene (CLNN) as of Nov 16, 2026 is -13,086.50 %. In the previous year, Pre-Tax Profit Margin was -11,520.47 % — a change of 13.59% (lower).

Pre-Tax Margin

-13,086.50 %

YoY

13.59%

Last updated:

Pre-Tax Profit Margin of Clene is 2025 -13,086.50 % . Pre-Tax Profit Margin of Clene was 2024 -11,520.47 % . It decreases by 13.59% lower compared to the previous year.

The Clene Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2020
-9,160.68 USD
Jan 1, 2021
-1,406.36 USD
Jan 1, 2022
-6,325.16 USD
Jan 1, 2023
-7,569.42 USD
Jan 1, 2024
-11,520.47 USD
Jan 1, 2025
-13,086.50 USD
The Clene Pre-Tax Margin history
YEARPre-Tax MarginYoY
-13,086.50 %+13.59%
-11,520.47 %+52.20%
-7,569.42 %+19.67%
-6,325.16 %+349.75%
-1,406.36 %-84.65%
-9,160.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Pre-Tax Profit Margin of Clene is -13,086.50 % in 2025.

Pre-Tax Profit Margin of Clene changed from -11,520.47 % to -13,086.50 %, representing a 13.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Clene since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Clene with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Clene

All Key Metrics — Clene